honeycomb shape
An Open Letter from NGM Leadership on Standing Up to Bigotry, Racism and Prejudice

ABOUT US

Welcome to NGM Bio

We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.

We are intensely science-driven and committed to having a profound impact on addressing some of today’s most urgent medical needs.

right image of girl

We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that will enable us to move rapidly into proof-of-concept studies and deliver first-in-class medicines. We aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs already in clinical development. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. But we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines and building our proficiency in discovery research.

Our Team

Our management team, scientists, board members and advisors have extensive track records of successfully discovering, developing and delivering to patients multiple, class-defining drugs with meaningful clinical and commercial impact, which positions us well to maximize the potential of our drug discovery approach.

William J. Rieflin

Executive Chairman

David J. Woodhouse, Ph.D.

Chief Executive Officer

Jin-Long Chen, Ph.D.

Founder and Chief Scientific Officer

Alex DePaoli, M.D.

Senior Vice President, Chief Translational Officer

Marc Learned, Ph.D.

Vice President, Research Operations

Hsiao D. Lieu, M.D.

Senior Vice President, Chief Medical Officer

Siobhan Nolan Mangini

Chief Financial Officer

Brian Muma

Vice President, Human Resources

Valerie Pierce

Senior Vice President, General Counsel and Chief Compliance Officer

Hui Tian, Ph.D.

Senior Vice President, Research

Board of Directors

William J. Rieflin

Executive Chairman, NGM Biopharmaceuticals

David V. Goeddel, Ph.D.

Managing Partner, The Column Group

Jin-Long Chen, Ph.D.

Founder and Chief Scientific Officer, NGM Biopharmaceuticals

Shelly Guyer

Chief Financial Officer, Invitae Corporation

Carole Ho, M.D.

Chief Medical Officer & Head of Development, Denali Therapeutics

Suzanne Sawochka Hooper

Former Executive Vice President and General Counsel, Jazz Pharmaceuticals

Mark Leschly

Managing Partner, RHO Capital Partners

Roger M. Perlmutter, M.D., Ph.D.

CEO, Eikon Therapeutics

David J. Woodhouse, Ph.D.

Chief Executive Officer, NGM Biopharmaceuticals

Scientific Advisory Board

Michael S. Brown, M.D.

Chairman

Michael Fischbach, Ph.D.

Joseph L. Goldstein, M.D.

Robert D. Schreiber, Ph.D.

Special Advisors

Grant Heidrich

Arthur D. Levinson, Ph.D.

Top